LML4805 Assignment 2 (COMPLETE ANSWERS) Semester 1 2026 - DUE April 2026; 100% Correct solutions and explanations.

LML4805 Assignment 2 (COMPLETE ANSWERS) Semester 1 2026 - DUE April 2026; 100% Correct solutions and explanations.LML4801 Patent and Copyright Law Assignment 2, First semester 2026 Due Date: 6 April 2026 (to be confirmed via an announcement) 20 marks, max 600 words (about 1,25 pages, excluding the cover page, footnotes and bibliography) This assignment is about Lesson 3 PATENTS, in conjunction with Lesson 1 INTRODUCTION. You will note that the Assignment 2 question relates to the LML4801 specific outcomes (as they relate to patent law) – 1. Identify and investigate the role of patents in current South African law and everyday life. 2. Demonstrate a critical understanding of the history and theoretical framework of, and the most pressing and prevalent issues regarding patent law. 3. Apply the principles of patent law in practical situations to solve multi- dimensional legal problems associated with patents. 4. Conduct research on matters pertaining to patents. (See Tutorial Letter LML4ALL /101/3/2026 at 2.2 Outcomes on p 8.) Your assignment answer must be typed in Arial font, size 12 with single line spacing within the paragraph, and double line spacing after the paragraph. Your answer for the whole assignment should not exceed 600 words, which is about 1,25 typed pages in the format prescribed above. 600 words is enough for answering this assignment. Plan carefully. Accurate answers and precise references (including page and paragraph numbers) are required. Credit will be given for meaningful references to relevant South African legislation, court decisions and scholarly opinion (textbooks and articles). Only refer to foreign and international law if it can add meaningfully to your comprehensive engagement with South African law. Acknowledge your sources in footnotes or in the text itself, and in your bibliography at the end of the assignment. For this assignment, please use the footnotes for referencing only and not for furthering your argument. Suggested style: see Tutorial Letter 301/4/2024 General information and referencing guide for all students in the School of Law. Your footnotes, cover page and bibliography are excluded from the 600-word limit. Do not list any sources in your bibliography that you have not consulted directly. DO NOT CUT AND PASTE ANSWERS FROM THE LESSONS OR ANY OTHER SOURCE. You may not repeat the wording from any source, including the study material, without properly attributing it as a quotation. As no marks (or few marks only) will be given for direct quotations from any source, long quotations are an absolute waste of precious space. It is imperative to use your own words to convey your understanding of the work. Unacknowledged copying/plagiarism or any other forms of cheating will lead to a 0 mark. As the aim of the assignment is to engage with the prescribed study material and formulate your own response to the question, the use of Artificial Intelligence is not allowed. Scenario Dr Dlamini is a marine biologist at the South African research institution, the Cape Institute of Deep-Sea Sciences (CIDSS), based in Cape Town. For several years, Dr Dlamini has been conducting research into bioluminescent proteins produced by a deep-sea cephalopod species discovered in the Benguela Current off the West Coast of South Africa. She names the species Bathysepia luminos for purposes of her work. The species produces a photoprotein (which Dr Dlamini names ‘Nalequorin’) that emits a uniquely stable bluespectrum light signal even at temperatures exceeding 60°C. Naturally occurring photoproteins isolated from marine organisms, such as aequorin from the jellyfish Aequorea victoria, have long been characterised in the scientific literature and used in biomedical research. After isolating Nalequorin from Bathysepia luminos, Dr Dlamini works with a pharmaceutical chemistry colleague to develop a process by which purified Nalequorin is encapsulated within a lipid nanoparticle carrier system to enable its use as a targeted, excitation-free bioimaging agent capable of detecting tumour cells in deep tissue in live animal models. The nanoparticle encapsulation method she uses is adapted from a well-established lipid nanoparticle delivery framework previously developed and published for the delivery of mRNA vaccines (the ‘Kaur-Ndlovu Framework’), which had been described in detail in a